文献速递烧伤创面修复

碱性成纤维细胞生长因子治疗深二度烧伤的安全性与疗效

Safety and efficacy of basic fibroblast growth factors for deep second-degree burn patients.
PubMed 文献 · Burns · 2020-06-26

韩国15家医院6年上市后监测研究纳入3173例患者,其中1630例深二度烧伤患者评估bFGF安全性,不良事件发生率2.3%,均为轻度且与bFGF可能无关。再上皮化平均8天,大面积烧伤较长;99.8%创面改善。间接比较显示bFGF再上皮化时间优于培养表皮自体移植。

要点

  • bFGF喷雾治疗深二度烧伤不良事件率2.3%,均为轻度。
  • 再上皮化平均8天,大面积烧伤9.7天较长。
  • 间接比较bFGF再上皮化7.1天优于CEA的13.7天。

核心结论

  • bFGF是深二度烧伤具有竞争力的再生疗法,临床疗效和安全性良好,可缩短治疗时间。

研究设计与样本

  • 韩国15家医院6年上市后监测研究,共3173例患者,其中1630例深二度烧伤患者评估不良事件。
  • 疗效按再上皮化时间评估,并与培养表皮自体移植进行间接比较。

主要发现

  • 37例(2.3%)发生不良事件,包括应用部位疼痛(1.7%)和接触性皮炎(0.6%),均为轻度且评估为与bFGF可能无关。
  • 再上皮化平均时间为8天,大面积烧伤(9.7天)显著长于小面积(7.8天)和中面积(7.9天)。
  • 99.8%的治疗创面评估为改善。
  • 间接比较中bFGF应用天数(5.4 vs. 8.8天)和再上皮化时间(7.1 vs. 13.7天)均显著短于CEA。

临床怎么用

  • bFGF可用于深二度烧伤的再生治疗,需关注应用部位疼痛和接触性皮炎等轻度不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Burn injuries are common afflictions; however, conservative wound care frequently leads to poor treatment compliance and physical disability in deep burn patients. Therefore, regenerative biologic materials, which are more effective for tissue repair, are required, particularly for deep second-degree burns. A novel spray formulation of basic fibroblast growth factors (bFGF) was produced by synthesizing fibroblast growth factor proteins. In this post-marketing surveillance (PMS) study, we assessed the safety and efficacy of bFGF and indirectly compared this formulation with cultured epidermal autografts (CEAs) for treating deep second-degree burns. MATERIALS AND METHODS: A total of 3173 patients treated at 15 hospitals were used for PMS of bFGF in South Korea for six years. In total, 1630 patients with deep second-degree burns were selected for assessing adverse events (AEs) of bFGF treatments. Efficacy was evaluated according to time periods until re-epithelialization, and clinical usefulness of bFGF was indirectly compared with that of CEAs. RESULTS: AEs occurred in 37 patients (2.3%) and included application site pain (1.7%) and contact dermatitis (0.6%). All AEs were mild and were evaluated as probably unrelated with bFGF. The average time for re-epithelialization was 8 days; this time span was significantly longer after major burns (9.7 days) than after minor (7.8 days) or moderate burns (7.9 days). Most treated burn wounds (99.8%) were assessed as improved. The indirect comparison included 534 patients using the same inclusion criteria for CEA patients (n = 35). The bFGF treatment demonstrated superior efficacy compared to CEAs by significantly reducing the average day to application (5.4 vs. 8.8 days) and re-epithelialization time (7.1 vs. 13.7 days). CONCLUSION: Our study demonstrated that bFGF is a compelling regenerative therapy with competitive clinical efficacy and safety for deep second-degree burns and reduced treatment time, which is expected to reduce medical costs, particularly for deep second-degree burn patients.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Ahn HN, Kang HS, Park SJ, et al. Safety and efficacy of basic fibroblast growth factors for deep second-degree burn patients. Burns. 2020. PMID: 33054995. doi:10.1016/j.burns.2020.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。